CarepathRx and UPMC announce landmark partnership

Dec. 2, 2020

CarepathRx announced it will acquire the management services organization responsible for the operational and strategic management of Chartwell while UPMC becomes a strategic investor in CarepathRx. 

CarepathRx, a pharmacy and medication management solutions company for vulnerable and chronically ill patients, stated the partnership with UPMC’s Chartwell subsidiary that will expand patient access to innovative specialty pharmacy and home infusion services. By focusing on the most vulnerable patients, CarepathRx is seeking to break down the barriers of typical pharmacy care and medication management. Its suite of solutions caters to patients undergoing specialty and infusion therapies, often for a variety of chronic conditions.

Today, CarepathRx delivers its services to more than 600 hospitals across the country. This new partnership expands CarepathRx’s specialty and home infusion capabilities.

“Our partnership with UPMC and Chartwell is an important step for CarepathRx. We set out to create a new approach to pharmacy care in the market—one that is centered on the patient and that works collaboratively with both the provider and the payor of healthcare,” said Figueroa, chief executive officer of CarepathRx. “We welcome the team at Chartwell to the CarepathRx family and are thrilled to partner with UPMC to help us achieve our mission.” The transaction is expected to close within 30 days, and terms were not disclosed. Cantor Fitzgerald & Co. served as financial advisor to Chartwell in the formation of the management services organization and partnership with CarepathRx.

UPMC has the release.